Avivagen Inc. VIVXF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 68.44% | -45.43% | -47.21% | -30.85% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.44% | -45.43% | -47.21% | -30.85% | -- |
| Cost of Revenue | 80.47% | -45.12% | -46.40% | -32.50% | -- |
| Gross Profit | 54.42% | -45.93% | -48.35% | -28.53% | -- |
| SG&A Expenses | -40.76% | -17.83% | -3.69% | 9.42% | -- |
| Depreciation & Amortization | -39.47% | -30.64% | -33.58% | -31.35% | -- |
| Other Operating Expenses | 75.65% | 73.51% | 69.49% | 73.60% | -- |
| Total Operating Expenses | -34.80% | -19.88% | -8.16% | 5.35% | -- |
| Operating Income | 43.16% | 12.60% | -3.99% | -16.94% | -- |
| Income Before Tax | 32.23% | 8.07% | 18.37% | 7.22% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.23% | 8.07% | 18.37% | 7.22% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.23% | 8.07% | 18.37% | 7.22% | -- |
| EBIT | 43.16% | 12.60% | -3.99% | -16.94% | -- |
| EBITDA | 42.68% | 11.67% | -5.27% | -18.26% | -- |
| EPS Basic | 37.59% | 14.86% | 22.53% | 13.49% | -- |
| Normalized Basic EPS | 34.29% | 12.17% | 20.44% | 13.20% | -- |
| EPS Diluted | 37.59% | 14.86% | 22.53% | 13.49% | -- |
| Normalized Diluted EPS | 34.29% | 12.17% | 20.44% | 13.20% | -- |
| Average Basic Shares Outstanding | 17.28% | 14.15% | 8.84% | 7.09% | -- |
| Average Diluted Shares Outstanding | 17.28% | 14.15% | 8.84% | 7.09% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |